Modi’in, Israel, Dec. 31, 2015 – Silenseed, a leading RNAi-based therapeutics company, today announced the construction of a class-A GMP clean room facility in the new company office Modi’in....
Striving for a better future Silenseed is dedicated towards developing
novel drugs that target personalized treatment for solid tumors.
Harnessing new scientific horizons we develop solutions for both
untreated cancers and innovative ways for (RNAi) drug delivery.
Phase II Clinical Trial for Pancreatic Cancer –
Currently Available for stage 3 patients
For more details
Motivated by the challenges facing RNAi delivery, Silenseed has developed a novel drug delivery platform LODER™ which enables the insertion of RNAi therapeutic pharmaceuticals directly into the core of solid tumors
With patients in mind – Silenseed is dedicated towards developing novel drugs that harness new scientific horizons developing solutions for untreated cancers